Balyasny Asset Management
VTVT icon

Balyasny Asset Management’s vTv Therapeutics VTVT Stock Holding History

Balyasny Asset Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-605
Closed -$98K – 2180
2018
Q1 		$98K Buy
+605
New +$148K ﹤0.01% 1831

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Balyasny Asset Management's VTVT Position: Q2 2018 in Review

Balyasny Asset Management sold out of vTv Therapeutics (VTVT) in Q2 2018, closing a stake of 605 shares — an estimated $98K sold.

Balyasny Asset Management first reported a position in VTVT in Q1 2018 and held it in 1 quarter. The position peaked at $98K in Q1 2018. 27 funds tracked by Wall St. Rank hold VTVT as of Q2 2018.

  • Balyasny Asset Management reported no remaining vTv Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 605 vTv Therapeutics shares in Q2 2018, an estimated $98K.
  • Balyasny Asset Management first reported a position in vTv Therapeutics in Q1 2018 and held it in 1 quarter.
  • Balyasny Asset Management's vTv Therapeutics position peaked at $98K in Q1 2018.
  • 27 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.